{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:26Z","timestamp":1791308186397,"version":"4.3.1"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,5,24]]},"DOI":"10.18632\/oncotarget.9171","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T19:54:21Z","timestamp":1462564461000},"page":"29916-29926","source":"Crossref","is-referenced-by-count":44,"title":["Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity"],"prefix":"10.18632","volume":"7","author":[{"given":"Ronit","family":"Mazor","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Onda","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Park","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"New Business Development Department, Medytox Inc., Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamawit","family":"Addissie","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiman","family":"Xiang","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Thoracic and GI Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"Thoracic and GI Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Willingham","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Ho","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"andactivity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"5","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Pastan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"6","first-page":"208ra147","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Pastan","year":"2013","journal-title":"Sci Transl Med"},{"key":"7","first-page":"21","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Nadler","year":"2016","journal-title":"Front Immunol"},{"key":"8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Pastan","year":"2016","journal-title":"Immunol Rev"},{"key":"9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/01.CIR.94.2.197","article-title":"Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization","volume":"94","author":"Verstreken","year":"1996","journal-title":"Circulation"},{"key":"10","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1073\/pnas.1102746108","article-title":"Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes","volume":"108","author":"Pastan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Pastan","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.4049\/jimmunol.172.11.6658","article-title":"Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in anresponse directed at the subdominant epitope","volume":"172","author":"Harding","year":"2004","journal-title":"J Immunol"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.91.","article-title":"Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies","author":"Pastan","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"14","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Pastan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1535-7163.MCT-15-0532","article-title":"Recombinant immunotoxin with T-cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumors","volume":"14","author":"Pastan","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"16","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Pastan","year":"2009","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Hassan","year":"2014","journal-title":"Cancer Res"},{"key":"18","first-page":"5151","article-title":"Loss of mesothelin expression by mesothelioma cells growndetermines sensitivity to anti-mesothelin immunotoxin SS1P","volume":"32","author":"Hassan","year":"2012","journal-title":"Anticancer Res"},{"issue":"1 Pt 1","key":"19","first-page":"16","article-title":"Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1","volume":"10","author":"Pastan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1745-7580-6-6","article-title":"Identification of conformational B-cell Epitopes in an antigen from its primary sequence","volume":"6","author":"Raghava","year":"2010","journal-title":"Immunome Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmbi.1998.1843","article-title":"Anatomy of hot spots in protein interfaces","volume":"280","author":"Thorn","year":"1998","journal-title":"J Mol Biol"},{"key":"22","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4049\/jimmunol.168.5.2530","article-title":"Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus","volume":"168","author":"Datta","year":"2002","journal-title":"J Immunol"},{"key":"23","doi-asserted-by":"crossref","first-page":"e0115582","DOI":"10.1371\/journal.pone.0115582","article-title":"Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B\/E","volume":"10","author":"Robb","year":"2015","journal-title":"PloS One"},{"key":"24","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4049\/jimmunol.143.8.2663","article-title":"I-Ad restricted T cell recognition of influenza hemagglutinin. Synthetic peptides identify multiple epitopes corresponding to antibody-binding regions of the HA1 subunit","volume":"143","author":"Thomas","year":"1989","journal-title":"J Immunol"},{"key":"25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/327713a0","article-title":"Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope","volume":"327","author":"Unanue","year":"1987","journal-title":"Nature"},{"key":"26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/intimm\/8.2.177","article-title":"Identification of a putative motif for binding of peptides to HLA-DQ2","volume":"8","author":"Sollid","year":"1996","journal-title":"Int Immunol"},{"key":"27","doi-asserted-by":"crossref","first-page":"D405","DOI":"10.1093\/nar\/gku938","article-title":"The immune epitope database (IEDB) 3. 0","volume":"43","author":"Peters","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"28","first-page":"9","article-title":"Isolation of anti-mesothelin antibodies from a phage display library","volume":"34","author":"Pastan","year":"1997","journal-title":"MolImmunol"},{"key":"29","first-page":"503","article-title":"Recombinant immunotoxins in the treatment of cancer","volume":"248","author":"Bera","year":"2004","journal-title":"Methods Mol Biol"},{"key":"30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4049\/jimmunol.1000405","article-title":"Molecular determinants of T cell epitope recognition to the common Timothy grass allergen","volume":"185","author":"Sette","year":"2010","journal-title":"J Immunol"},{"key":"31","doi-asserted-by":"crossref","first-page":"E3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Pastan","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Pastan","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T23:25:24Z","timestamp":1692314724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":32,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,5,24]]}},"alternative-id":["9171","27167198"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9171","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]}}}